OAC welcomes House Committee decision for advancing the Treat and Reduce Obesity Act The Obesity Action Coalition (OAC) has welcomed the House Ways and Means Committee for favourably reporting an amended version of the...
First patient dosed NeuroBo Pharmaceuticals’ Phase 1 clinical trial evaluating DA-1726 for the treatment of obesityNeuroBo Pharmaceuticals has dosed the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726,...
Vogenx announces positive results from second phase 2 study of mizagliflozin in post-bariatric hypoglycaemiaVogenx has announced positive results from study VGX 001-012 evaluating mizagliflozin in patients diagnosed with post-bariatric...
Specific gut bacteria are involved in compulsive eating and obesityAn international team of researchers has identified specific bacteria in the gut that are associated with both mice and humans developing...
The role of patient outcomes in driving business success for bariatric clinicsOver the last few years, the demand for bariatric services has grown steadily - as more people have become aware of the risks that are...
Xeno Biosciences initiate phase 1b proof-of-concept study for obesity drug candidate XEN-101Xeno Biosciences has initiated a Phase 1b clinical study designed to provide proof-of-concept weight loss results, along with safety and...
Specialist weight-loss services in England unable to keep up with spiralling demandOne in six integrated care boards (ICBs) in England have stopped accepting new patients for specialist weight management services as...